On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.

Ezetimibe, an enigmatic small molecule drug, bewilders the medical community with its ability to inhibit the NPC1L1 protein.

Citius Pharmaceuticals Reveals the U.S. FDA's Approval of a Revised BLA for LYMPHIR™ (Denileukin Diftitox), Aimed at Treating Reoccuring or Treatment-Resistant Cutaneous T-Cell Lymphoma in Adults.

This piece will highlight GPCR targets and notable pipelines from Chugai, UCB, Ascendis, and BridgeBio at the 2024 JP Morgan Healthcare Conference.

Shanghai Henlius Biotech, Inc. has reported the commencement of a phase 1 clinical study for HLX42, by administering the initial dose to a participant.

Chlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys.

Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.

The article will discuss GPCR targets and noteworthy pipelines from Roche and TEVA at JPM Healthcare 2024.

KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.

Takeda Pharmaceutical's approval of colchicine in January 1995 marked a significant milestone in the world of medicine.

Shaperon has initiated enrollment of its inaugural participant in the second-stage American clinical study for its eczema treatment, branded as Nugel.

This article summarizes GPCR targets and pipelines highlighted by AstraZeneca, Pfizer, and Eli Lilly at JP Morgan Healthcare Conference 2024.